항응고제 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the anticoagulants market size is estimated at USD 37.56 billion in 2026, and is expected to reach USD 51.13 billion by 2031, at a CAGR of 6.36% during the forecast period (2026-2031).

This report is Segmented by Drug Class (Novel Oral Anticoagulants, Heparin & LMWH, Vitamin K Antagonists, Factor XIa Inhibitors, Parenteral Direct Thrombin Inhibitors), Route of Administration (Oral, Injectable, and More), Application (Atrial Fibrillation & Myocardial Infarction, and More), Distribution Channel (Hospital, and More), and Geography. Market Forecasts are Provided in Terms of Value (USD).

Global Anticoagulants Market Trends and Insights

Growing Prevalence of Cardiovascular Diseases & Atrial Fibrillation

Global atrial fibrillation cases reached 59.7 million in 2024 and continue to climb as populations age and metabolic syndrome spreads in middle-income nations. Updated 2024 European guidelines lowered oral anticoagulation thresholds, enlarging the eligible pool by about 15%. U.S. stroke data show AF-related events carry 30-day mortality above 25%, steering payers toward preventive therapy. Added pressure comes from rising heart failure with preserved ejection fraction, a condition that typically coexists with AF. Growing use of wearables with AF detection algorithms further boosts diagnosis rates. Together, these factors sustain long-term demand that outlasts the current forecast window.

Rapid Adoption of NOACs Over Warfarin

Direct oral agents account for more than 70% of new U.S. prescriptions as of 2025, driven by reduced monitoring burdens and superior safety profile. Combined global sales of apixaban, rivaroxaban, edoxaban, and dabigatran exceeded USD 15 billion in 2024, even before widespread generic entry. Scientific bodies report roughly 50% lower intracranial hemorrhage rates versus warfarin, reinforcing clinician confidence. Warfarin use is now largely limited to mechanical heart valves, severe renal impairment, or antiphospholipid syndrome. Imminent generic launches are expected to drive price parity in cost-sensitive regions, accelerating the switch.

Patent Expiries & Generic Erosion of Key NOACs

Apixaban lost exclusivity in several EU states in 2024, trimming branded revenue by about 30% within 12 months. Rivaroxaban experienced similar pressure as generics gained a 25% volume foothold, leading to a 12% revenue drop for Bayer in Europe. U.S. patent cliffs in 2026 will extend these pricing pressures. Manufacturers respond by investing in patient-support apps and real-world evidence to defend brand value. While margins shrink, lower prices broaden access in lower-income markets, moderating the negative impact on overall growth.

Other drivers and restraints analyzed in the detailed report include:

1. Favorable Clinical Guidelines for VTE Prophylaxis
2. AI-Driven Personalized Anticoagulation Dosing Tools
3. Bleeding-Risk Concerns Limiting Adoption

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Factor XIa inhibitors are poised for an 8.33% CAGR between 2026 and 2031, the fastest among classes, as drug makers seek to uncouple efficacy from bleeding risk. Bayer's asundexian did not meet the primary endpoint for non-inferiority versus apixaban in 2024, yet mechanistic validation kept competitors engaged. Bristol-Myers Squibb and Janssen push milvexian through late-stage trials, and Anthos Therapeutics' monthly abelacimab continues to show encouraging safety. Novel Oral Anticoagulants retained 42.53% of 2025 revenue, but rising volumes will not fully offset erosion from generic entry. Meanwhile, heparins remain acute-care staples, and vitamin K antagonists settle into niche roles. This bifurcation yields a price-competitive high-volume NOAC segment and a premium high-growth Factor XIa segment set to redefine therapeutic ceilings.

Second-generation biologics such as antisense oligonucleotides target infrequent dosing, offering potential differentiation once safety is established. However, regulatory clarity on long-term gene-silencing is still evolving. The anticoagulants market overall must balance established blockbuster categories with emergent therapies likely to command premium pricing if they deliver superior safety.

Oral agents captured 59.37% of 2025 revenue due to patient preference and fixed dosing convenience. Yet, implantable and long-acting delivery solutions are expanding at a 9.67% CAGR as companies pursue depot technologies that alleviate daily pill fatigue. The FDA cleared a 7-day extended-release subcutaneous Factor Xa formulation in 2024 for post-surgical prophylaxis, reducing nursing burden and early discharge risks.

Research into biodegradable microspheres and biomarker-responsive ports aims to tackle the 30% discontinuation rate observed within the first year of oral therapy. Regulatory pathways for combination drug-device products remain complex, requiring parallel submissions to different FDA centers, which slows commercialization. Despite these hurdles, innovators view implantables as strategic hedges in a landscape where traditional tablets face generic commoditization.

Complete Report Scope:

• By Drug Class
  • Novel Oral Anticoagulants (NOACs)
  • Heparin & Low-Molecular-Weight Heparin (LMWH)
  • Vitamin K Antagonists
  • Factor XIa Inhibitors
  • Parenteral Direct Thrombin Inhibitors
• By Route of Administration
  • Oral Anticoagulants
  • Injectable Anticoagulants
  • Implantable / Long-acting Delivery Systems
• By Application
  • Atrial Fibrillation & Myocardial Infarction
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Cancer-Associated Thrombosis
  • Mechanical Heart Valves & Other Cardiac Uses
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 32.65% of 2025 revenue, anchored by broad NOAC coverage under Medicare Part D and private value-based contracts tied to adherence metrics. Canada's 2024 formulary expansion boosted volumes, while Mexico negotiated bulk deals with generic makers to reach cost parity with warfarin. Growth will gradually moderate as penetration nears saturation, yet profitability remains highest due to favorable pricing dynamics.

Europe followed, with Germany, the United Kingdom, France, Italy, and Spain accounting for more than 60% of regional revenue. EU approval of generic apixaban and rivaroxaban in 2024 drove price cuts of 40-50% in substitution-mandated markets. The U.K. designated NOACs as first-line therapy, prompting an 18% prescription increase despite cheaper generics. Geopolitical tensions disrupted supply in Eastern Europe, forcing reliance on local warfarin and heparin production.

Asia-Pacific is the fastest-growing region, set for an 8.37% CAGR, driven by broad reimbursement wins. China added edoxaban to the national reimbursement list in 2025, slashing patient out-of-pocket costs by 70%. Japan granted priority review to a reduced-dose apixaban formulation tailored to body-weight profiles, addressing previous bleeding concerns. India's generic launches at 60% lower price points are unlocking demand in tier-2 and tier-3 cities. Australia's expanded subsidies lifted prescription volumes 22% in early 2025.

The Middle East & Africa and South America remain nascent, constrained by affordability and regulatory fragmentation. Pilot reimbursement programs in Gulf Cooperation Council states and Brazil indicate early but promising expansion opportunities beyond 2031. Collectively, these diverse trajectories reinforce a global anticoagulants market that balances mature high-value regions with rapidly scaling emerging economies.

1. Alexion Pharmaceuticals Inc.
2. Anthos Therapeutics
3. Aspen Pharma Holdings Ltd.
4. Astellas Pharma
5. Bayer
6. Boehringer Ingelheim
7. Bristol-Myers Squibb
8. Daiichi Sankyo Co. Ltd.
9. Dr. Reddy's Laboratories
10. Roche
11. Ionis Pharmaceuticals
12. Johnson & Johnson
13. Leo Pharma
14. Merck
15. Mitsubishi Tanabe Pharma
16. Nektar Therapeutics
17. Novartis
18. Pfizer
19. Sanofi

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Growing Prevalence of Cardiovascular Diseases & Atrial Fibrillation
  • 4.2.2 Rapid Adoption of NOACs Over Warfarin
  • 4.2.3 Rising Geriatric Population Globally
  • 4.2.4 Favorable Clinical Guidelines for VTE Prophylaxis
  • 4.2.5 AI-Driven Personalized Anticoagulation Dosing Tools
  • 4.2.6 Extended Outpatient Thromboprophylaxis Post-COVID-19
• 4.3 Market Restraints
  • 4.3.1 Patent Expiries & Generic Erosion of Key NOACs
  • 4.3.2 Bleeding-Risk Concerns Limiting Adoption
  • 4.3.3 Porcine-Heparin Supply-Chain Vulnerability
  • 4.3.4 Regulatory Uncertainty For RNAi / Gene-Silencing Agents
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value - USD)

• 5.1 By Drug Class
  • 5.1.1 Novel Oral Anticoagulants (NOACs)
  • 5.1.2 Heparin & Low-Molecular-Weight Heparin (LMWH)
  • 5.1.3 Vitamin K Antagonists
  • 5.1.4 Factor XIa Inhibitors
  • 5.1.5 Parenteral Direct Thrombin Inhibitors
• 5.2 By Route of Administration
  • 5.2.1 Oral Anticoagulants
  • 5.2.2 Injectable Anticoagulants
  • 5.2.3 Implantable / Long-acting Delivery Systems
• 5.3 By Application
  • 5.3.1 Atrial Fibrillation & Myocardial Infarction
  • 5.3.2 Deep Vein Thrombosis
  • 5.3.3 Pulmonary Embolism
  • 5.3.4 Cancer-Associated Thrombosis
  • 5.3.5 Mechanical Heart Valves & Other Cardiac Uses
• 5.4 By Distribution Channel
  • 5.4.1 Hospital Pharmacies
  • 5.4.2 Retail Pharmacies
  • 5.4.3 Online Pharmacies
  • 5.4.4 Specialty Clinics
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Alexion Pharmaceuticals Inc.
  • 6.3.2 Anthos Therapeutics
  • 6.3.3 Aspen Pharma Holdings Ltd.
  • 6.3.4 Astellas Pharma Inc.
  • 6.3.5 Bayer AG
  • 6.3.6 Boehringer Ingelheim GmbH
  • 6.3.7 Bristol-Myers Squibb
  • 6.3.8 Daiichi Sankyo Co. Ltd.
  • 6.3.9 Dr. Reddy's Laboratories Ltd.
  • 6.3.10 F. Hoffmann-La Roche AG
  • 6.3.11 Ionis Pharmaceuticals Inc.
  • 6.3.12 Johnson & Johnson (Janssen)
  • 6.3.13 Leo Pharma A/S
  • 6.3.14 Merck & Co. Inc.
  • 6.3.15 Mitsubishi Tanabe Pharma
  • 6.3.16 Nektar Therapeutics
  • 6.3.17 Novartis AG
  • 6.3.18 Pfizer Inc.
  • 6.3.19 Sanofi SA

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment